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Abstract
Purpose The vascular endothelial growth factor A (VEGFA)
is crucial for normal vasculogenesis and angiogenesis during
pregnancy, and alterations in the VEGFA gene expression
were detected in women with idiopathic recurrent spontane-
ous abortion (IRSA) and spontaneously aborted conceptuses.
Our aim was to evaluate whether there is an association be-
tween the functional −2549 insertion/deletion (I/D) polymor-
phism in the promoter region of the VEGFA gene and IRSA in
reproductive couples.
Methods We performed a case-control study involving 149
women and their 140 partners with three or more IRSA and
149 control women and men. Allele-specific polymerase
chain reaction was used for genotyping.
Results We found no association of the −2549 I/D polymor-
phism with IRSA in women. However, men with the DD ge-
notype have a 1.75-fold increased risk of IRSA compared with
men carrying the ID and II genotypes (95% confidence interval
(CI)=1.05–2.93, P=0.032). In addition, the D allele in men
contributes to a 1.42-fold increased risk of IRSA (95 % CI=
1.02–1.97, P=0.036) compared to men carrying the I allele.
Conclusions Our results indicate that the −2549 I/D polymor-
phism in the VEGFA gene in men might be associated with
IRSA. Additional genetic association studies including both
partners, as well as expression studies, are needed to elucidate
the role of this polymorphism in IRSA.
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Introduction
Recurrent spontaneous abortion (RSA) is a pregnancy com-
plication that includes at least three consecutive spontaneous
abortions [1]. Despite numerous researches, only
antiphospholipid syndrome, structural uterine anomalies, and
parental chromosomal anomalies have been confirmed as
causes of RSA and can be identified in 40 % of couples [1].
Genetic variability has been proposed as a predisposing factor
for idiopathic RSA (IRSA), and over a hundred candidate
genes were tested [2]. A large number of these genes are
involved in the regulation of angiogenesis at the feto-
placental unit.
Establishment of proper and sufficient blood flow in the
placenta is crucial for successful pregnancy outcome and de-
pends on appropriate vasculogenesis and angiogenesis, which
are mediated by diverse angiogenic factors, including vascular
endothelial growth factor A (VEGFA) [3]. Vascular endotheli-
al growth factor A is a major angiogenic factor secreted by
both maternal and fetal/trophoblastic cells, promoting endo-
thelial cell proliferation and survival, vascular permeability,
and hematopoesis [4, 5]. It has various functions in human
reproduction, including the regulation of fetal and placental
a n g i o g e n e s i s , a s w e l l a s g ame t o g e n e s i s a n d
(pre)decidualization [6]. The levels of VEGFA messenger
RNA (mRNA) and protein in the endometrium and placenta
differ in normal and complicated pregnancies, including
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IRSA, which might lead to abnormalities in angiogenesis dur-
ing implantation, placentation, and early pregnancy [3, 6]. The
altered gene expression in placenta suggests a potential con-
tribution of both parental genomes.
The VEGFA gene is highly polymorphic, and more than 25
different polymorphisms have been described [7]. Some of
these polymorphisms are functional and organized into haplo-
types. Genetic association with IRSAwas tested for 20 poly-
morphisms, among which, the most common are −1154 G/A,
+936 C/T, −2578 C/A, and −634 G/C single-nucleotide poly-
morphisms (SNPs). However, results of individual studies are
opposite. Meta-analyses indicate that +936 C/T, +583 T/C,
and −634 G/C SNPs in women might be predisposing factors
for IRSA, whereas the results for the −1154 G/A SNP are
inconsistent [8–10].
Although SNPs have been widely investigated in IRSA
and other reproductive disorders, there is an increasing interest
in the research of insertion/deletion (I/D) polymorphisms,
considering their contribution to genetic and phenotypic di-
vergence and diversity [11, 12]. It is estimated that there are
1.6–2.5 million I/D polymorphisms in the human genome,
making them an important source of genetic markers [12]. In
the VEGFA gene, a functional I/D polymorphism is located at
position −2549 in the promoter region [13]. Deletion of an 18
base pair (bp) long sequence (D allele) leads to a 1.95-fold
increased transcriptional activity compared to the allele con-
taining the insertion (I allele) [14].
Considering the important roles of VEGFA during pregnan-
cy and alterations in the VEGFA gene expression in IRSA
women and spontaneously aborted conceptuses, we aimed to
evaluate whether there is an association between the function-
al −2549 I/D polymorphism in the promoter region of the
VEGFA gene and IRSA in Slovenian reproductive couples.
Subjects and methods
Subjects
We performed a case-control study involving IRSA couples
and controls from the Slovenian population. The group of
IRSA couples consisted of 149 women and their 140 male
partners with three or more unexplained consecutive sponta-
neous abortions before the 22nd week of gestation. Exclusion
criteria were chromosomal anomalies in either partner, endo-
crine or metabolic disorders, antiphospholipid syndrome, au-
toimmune disease or other systemic diseases, previous venous
or arterial thrombosis, or structural uterine anomalies detected
by ultrasonography and/or hysteroscopy. A total of 98
(65.8 %) of couples had no live births (primary IRSA), where-
as 51 (34.2 %) had at least one live born child (secondary
IRSA). Ninety-two percent of couples had the spontaneous
abortions (SAs) in the first trimester and 8 % in the second
trimester. Couples were described in more detail previously
[15]. The control group consisted of 149 unrelated, healthy
women and men with at least two live births and no history of
SA or any other pregnancy complication. All women and men
were recruited through the Institute of Medical Genetics,
Department of Obstetrics and Gynaecology, UMC
Ljubljana, Slovenia, and written informed consent was obtain-
ed from all individual participants included in the study. The
study was approved by Slovenian and Croatian National
Ethics’ Committees.
Molecular genetic methods
Genomic DNAwas isolated from peripheral blood leukocytes
by standard procedures using a commercially available kit
(Qiagen_FlexiGene kit; QIAGEN GmbH, Hilden,
Germany). Genotyping was performed by allele-specific po-
lymerase chain reaction (PCR) as described previously [16].
The primers were 5′CCTGGAGCGTTTTGGTTAAA3′ and
5′ATATAGGAAGCAGCTTGGAA3′. All PCRs were carried
out in thermal cyclers (Mastercycle Personal, Eppendorf,
Hamburg, Germany, and 2720 Thermal Cycler, Applied
Biosystems, Carlsbad, CA, USA). The PCR products were
visualized under ultraviolet light after electrophoresis on 2 %
agarose gels, stained with GelRed™ (Olerup SSP®,
Saltsjöbaden, Sweden). Sizes of PCR products were 234 bp
for the I allele and 216 bp for the D allele (Fig. 1).
Statistical analysis
Statistical analyses were carried out using Statistica for
Windows, version 10 (StatSoft Inc., Tulsa, OK, USA) and
MedCalc for Windows, version 14.12.0 (MedCalc Software,
Fig. 1 Electrophoresis on 2 % agarose gel showing the PCR
amplification products for VEGFA −2549 I/D polymorphism. Lane 1,
100-bp DNA ladder. Lane 2, homozygote for deletion allele (DD)
(216 bp). Lane 3, homozygote for insertion allele (II) (234 bp). Lane 4,
heterozygote (ID) (234 and 216 bp)
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Mariakerke, Belgium). Statistical power was calculated using
DSS Researcher’s Toolkit (www.dssresearch.com/toolkit/
spcalc/power_p2.asp). Deviations from Hardy-Weinberg
equilibrium (HWE) were calculated using the Simple Hardy-
Weinberg Calculator–Court Lab (Washington State
University College of Veterinary Medicine, Pullman, WA,
USA). Pearson’s chi-squared (Χ2) test was used for the evalu-
ation of differences in genotype and allele frequencies be-
tween study groups. Odds ratios (ORs) and 95 % confidence
interval (CI) were calculated to test the associations of the −
2549 I/D polymorphism with the risk of IRSA under domi-
nant, recessive, and co-dominant genetic models. P values <0.
05 were considered statistically significant.
Results
The power of the present study was 100 % to detect a 2-fold
increase in the frequency of the I allele. There were no devi-
ations fromHWE in any of the study groups (data not shown).
Genotype and allele frequencies of the −2549 I/D polymor-
phism in the promoter region of the VEGFA gene in IRSA
couples and controls, as well as couples with primary and
secondary IRSAs, are shown in Tables 1 and 2. Statistically
significant higher frequency of the D allele was found in IRSA
men compared to controls (Χ2=4.06, P=0.044), whereas the
distribution of genotype frequencies were similar between
these two groups. The differences in genotype and allele fre-
quencies were not statistically significant between IRSA and
control women, women with primary and secondary IRSAs,
and men with primary and secondary IRSAs. The most
frequent genotype combination in IRSA couples regardless
of maternal and paternal origin was DD+ID (32.1 %).
The association of the −2549 I/D polymorphismwith IRSA
under dominant, recessive, and co-dominant genetic models is
shown in Tables 3 and 4. We found no association of the
polymorphism with IRSA in women under any model.
However, men with the DD genotype have a 1.75-fold in-
creased risk of IRSA compared with men carrying the ID
and II genotypes (recessive model) (95 % CI=1.05–2.93,
P=0.032). In addition, the D allele in men contributes to a
1.42-fold increased risk of IRSA (95 % CI=1.02–1.97, P=
0.036) compared to the I allele. Finally, there was no associ-
ation between the −2549 I/D polymorphism in men and pri-
mary or secondary IRSA under any genetic model.
Discussion
In the present case-control study, we tested the genetic asso-
ciation between the −2549 I/D polymorphism in the promoter
region of the VEGFA gene and IRSA in Slovenian reproduc-
tive couples. Our results indicate that the DD genotype in men
is associated with a 1.75-fold increased risk of IRSA com-
pared to men carrying the ID and II genotypes, making it a
potential predisposing factor for IRSA.
The −2549 I/D polymorphism has been extensively studied
in many diseases. The DD genotype was found to be associ-
atedwith breast cancer [17], diabetic retinopathy [18], diabetic
nephropathy [19], and Kawasaki disease [20], whereas the ID
genotype was associated with systemic sclerosis [21].
However, the association of the −2549 I/D polymorphism
Table 2 Genotype and allele frequencies of the VEGFA −2549 I/D polymorphism in IRSA and control men
Genotype/N (%) Allele/N (%)
Men DD ID II Χ2; P D I Χ2; P
IRSA
Control
49 (35.0)
35 (23.5)
58 (41.4)
70 (47.0)
33 (23.6)
44 (29.5)
4.75; 0.093 156 (55.7)
140 (47.0)
124 (44.3)
158 (53.0)
4.06; 0.044
Primary IRSA
Secondary IRSA
35 (38.5)
14 (28.6)
38 (41.7)
20 (40.8)
18 (19.8)
15 (30.6)
2.48; 0.289 108 (59.3)
48 (49.0)
74 (40.7)
50 (51.0)
2.37; 0.124
IRSA idiopathic recurrent spontaneous abortion, Χ2 chi square
Table 1 Genotype and allele frequencies of the VEGFA −2549 I/D polymorphism in IRSA and control women
Genotype/N (%) Allele/N (%)
Women DD ID II Χ2; P D I Χ2; P
IRSA
Control
54 (36.2)
46 (30.9)
63 (42.3)
68 (45.6)
32 (21.5)
35 (23.5)
0.96; 0.617 171 (57.4)
160 (53.7)
127 (42.6)
138 (46.3)
0.68; 0.410
Primary IRSA
Secondary IRSA
35 (34.7)
19 (37.3)
41 (41.8)
22 (43.1)
22 (22.5)
10 (19.6)
0.16; 0.922 111 (56.6)
60 (58.8)
85 (43.4)
42 (41.2)
0.06; 0.811
IRSA idiopathic recurrent spontaneous abortion, Χ2 chi-squared
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with IRSA was previously tested in only one study, which
included women of the South Indian population [22]. Similar
to our study, no statistically significant differences were found
in the distribution of genotype frequencies between IRSA and
control women. In addition, the association with IRSA under
different genetic models was not determined.
Although other polymorphisms of the VEGFA gene were
previously tested in many studies, our study is the first to
include male partners of IRSAwomen. Regardless of the fact
that most genetic association studies include only women,
recent evidence points to the importance of the male genome
in reproductive success [23] and particularly in the pathogen-
esis of IRSA [2, 24, 25]. This contribution most likely mani-
fests through the transmission of risk alleles through the feto-
placental unit to the embryo [23]. Interestingly, certain pater-
nal SNPs in the VEGF gene family increase the risk for preg-
nancy complications such as preeclampsia and small for ges-
tational age infants [26]. In addition, a number of different
paternal SNPs were found to be in strong association with
preeclampsia, indicating an important role of the male genome
in reproductive disorders [23]. Although the samples of spon-
taneously aborted conceptuses were not available to us for this
study, we can deliberate about the contribution of the DD
genotype in men to IRSA. Considering that both higher and
lower VEGF protein levels along with lower mRNA levels
were detected in the chorionic villi of spontaneously aborted
conceptuses compared with conceptuses obtained by induced
abortion [27–29], it is possible that the inheritance of the risk
D allele might lead to altered VEGFA gene expression in the
embryo. Consequently, this may lead to abnormal angiogene-
sis and spontaneous abortion.
Furthermore, a combined effect of both partners cannot be
excluded. Our analysis showed that the combination of DD and
ID genotypes is the most common combination in IRSA cou-
ples, and therefore, the transmission of the risk D allele in
homozygous or heterozygous form might contribute to sponta-
neous abortion. Although we also found a higher frequency of
the DD genotype in IRSAwomen compared to control women,
the difference did not reach statistical significance and was not
associated with IRSA under any genetic model. Nevertheless,
additional research is needed in different populations and on a
larger number of participants, especially because altered VEGF
mRNA and protein levels were detected in IRSAwomen com-
pared to control women, which might be under genetic control.
Women with IRSA have lower VEGF mRNA and protein
levels in the endometrium during the implantation window,
leading to abnormal vascular function [30–33]. On the contrary,
these women have higher serum VEGF protein levels, the sig-
nificance of which is not known [30, 31].
In addition to being a functional polymorphism, the −2549
I/D polymorphism is in perfect linkage disequilibrium with
the −2578 C/A SNP [13]. The I allele is linked with the
Table 4 Association of the VEGFA −2549 I/D polymorphism with IRSA in men
VEGFA I/D genetic model MIRSA vs. MC MPrimary IRSA vs. MSecondary IRSA
OR (95 % CI) P OR (95 % CI) P
Dominant
Recessive
Co-dominant
Alleles
DD+ID vs. II
DD vs. ID+II
DD vs. II
DD vs. ID
II vs. ID
D vs. I
1.36 (0.80–2.30)
1.75 (1.05–2.93)
1.87 (1.00–3.49)
1.69 (0.97–2.95)
0.74 (0.43–1.24)
1.42 (1.02–1.97)
0.253
0.032
0.051
0.064
0.253
0.036
1.79 (0.81–3.99)
1.56 (0.74–3.31)
2.08 (0.83–5.25)
1.31 (0.58–3.00)
0.56 (0.25–1.24)
1.52 (0.93–2.49)
0.152
0.243
0.119
0.513
0.152
0.097
95 % CI 95 % confidence interval, OR odds ratio,MC control men,MIRSA men with idiopathic recurrent spontaneous abortion, MPrimary IRSA men with
primary idiopathic recurrent spontaneous abortion, MSecondary IRSA men with secondary idiopathic recurrent spontaneous abortion
Table 3 Association of the
VEGFA −2549 I/D polymorphism
with IRSA in women
VEGFA I/D genetic model WIRSA vs. WC WPrimary IRSA vs. WSecondary IRSA
OR (95 % CI) P OR (95 % CI) P
Dominant
Recessive
Co-dominant
Alleles
DD+ID vs. II
DD vs. ID+II
DD vs. II
DD vs. ID
II vs. ID
D vs. I
1.12 (0.65–1.93)
1.27 (0.79–2.06)
1.28 (0.69–2.39)
1.27 (0.75–2.13)
0.99 (0.55–1.78)
1.16 (0.84–1.60)
0.677
0.327
0.429
0.374
0.965
0.365
0.84 (0.36–1.95)
0.93 (0.46–1.89)
0.84 (0.33–2.13)
0.99 (0.46–2.12)
1.18 (0.47–2.93)
0.91 (0.56–1.48)
0.689
0.853
0.709
0.976
0.721
0.717
95 % CI 95 % confidence interval, OR odds ratio, WC control women, WIRSAwomen with idiopathic recurrent
spontaneous abortion, WPrimary IRSAwomen with primary idiopathic recurrent spontaneous abortion, WSecondary
IRSAwomen with secondary idiopathic recurrent spontaneous abortion
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−2578 A allele, whereas the D allele is linked with the −2578
C allele. In the study by Eller et al. [34], there was a statisti-
cally significant higher frequency of the −2578 CC genotype
in IRSAwomen compared to control women, which suggests
that these women also have an increased frequency of the
−2549 DD genotype.
Our study has several strengths. The selection criteria for
couples were strict and based on exclusion of known causes of
RSA, including structural uterine anomalies, antiphospholipid
syndrome, and chromosomal anomalies in both partners.
Statistical power was sufficient, and the association between
the −2549 I/D polymorphism was conducted in Slovenian
population for the first time. Our study also included both
reproductive partners. On the other hand, one of the limita-
tions of this study is that genotyping was not performed on
spontaneously aborted conceptuses. Despite sufficient power
analysis, another limitation might be the sample size, which
might not allow us to detect minor effects. Therefore, before
any clinical guidance might be offered, additional genetic as-
sociation studies including both partners, as well as expression
studies, are needed to elucidate the role of VEGFA −2549 I/D
polymorphism in IRSA.
In conclusion, our results indicate that the −2549 I/D poly-
morphism in the promoter region of the VEGFA gene in men
might be associated with IRSA.
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